Redesign Health was founded in 2018 by Brett Shaheen. The company has not publicly endorsed plans to participate in an IPO.
Redesign Health describes itself as "a company that powers innovation in healthcare by developing technologies, tools, and insights that lower the barriers to change across the industry." By offering healthcare startups and entrepreneurs an alternative to traditional VC, Redesign Health helps support innovative medtech companies throughout all stages of growth. Redesign Health has raised more than $300 million in venture capital funding from investors including UPMC Enterprises, TriplePoint Capital, Samsung NEXT, General Catalyst, and Euclidean Capital. The company received a post-money valuation of $1.7 billion in late 2022.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
09/13/2022 | Series C-1 | $6,289 | $xx.xx | $1.7B | General Catalyst, CVS Health Ventures, UPMC Enterprises, Eden Global Partners, Euclidean Capital, Samsung Next, TriplePoint Capital, Declaration Partners | |
Price per Share
$xx.xx
Shares Outstanding
2,515,816
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
10.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
General Catalyst, CVS Health Ventures, UPMC Enterprises, Eden Global Partners, Euclidean Capital, Samsung Next, TriplePoint Capital, Declaration Partners
|
||||||
09/13/2022 | Series C | $65MM | $xx.xx | $1.7B | General Catalyst, CVS Health Ventures, UPMC Enterprises, Eden Global Partners, Euclidean Capital, Samsung Next, TriplePoint Capital, Declaration Partners | |
Price per Share
$xx.xx
Shares Outstanding
3,847,702
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
General Catalyst, CVS Health Ventures, UPMC Enterprises, Eden Global Partners, Euclidean Capital, Samsung Next, TriplePoint Capital, Declaration Partners
|
||||||
03/25/2021 | Series B | $94.88MM | $xx.xx | $454.64MM | Declaration Partners, Blisce | |
Price per Share
$xx.xx
Shares Outstanding
13,840,428
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Declaration Partners, Blisce
|
||||||
03/25/2021 | Series A | $2.66MM | $xx.xx | $454.64MM | Declaration Partners, Blisce | |
Price per Share
$xx.xx
Shares Outstanding
5,319,904
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Declaration Partners, Blisce
|